Maribavir: A novel benzimidazole ribonucleoside for the prevention and treatment of cytomegalovirus diseases

Antiviral Drug Strategies

Volumn 50, Issue , 2011, Pages 209-226

  Biron, Karen K ^a  

^a Pathfinder Pharmaceuticals Inc   (United States)

Author keywords

Antiviral activity; CMV retinitis; Cytomegalovirus; Herpes simplex virus; Maribavir; Novel mode of action; D riboside

Indexed keywords

EID: 85017432956     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527635955.ch9     Document Type: Chapter

References (90)

1. Mocarski, E.S., Jr., Shenk, T., and Pass, R.F. (2006) Cytomegaloviruses, in Fields Virology, 5th edn (eds D.M. Knipe and P.M. Howley), Lippincott Williams and Wilkins, Philadelphia, pp. 2701-2772.
2. Eid, A.J. and Razonable, R.R. (2010) New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs, 70, 965-981.
3. Hodge, W.G., Seiff, S.R., and Margolis, T.P. (1998) Ocular opportunistic infection incidences among patients who are HIV positive compared to patients who are HIV negative. Ophthalmology, 105, 895-900.
4. Fishman, J.A., Emery, V., Freeman, R., Pascual, M., Rostaing, L., Schlitt, H.J., Sgarabotto, D., Torre-Cisneros, J., and Uknis, M.E. (2007) Cytomegalovirus in transplantation: challenging the status quo. Clinical Transplantation, 21, 149-158.
5. Hodson, E.M., Craig, J.C., Strippoli, G.F., and Webster, A.C. (2008) Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database of Systematic Reviews, (2), CD003774, doi: 10.1002/14651858.CD003774.pub3.
6. Elion, G.B., Furman, P.A., Fyfe, J.A., de Miranda, P., Beauchamp, L., and Schaeffer, H.J. (1977) Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proceedings of the National Academy of Sciences of the United States of America, 74, 5716-5720.
7. Holbrook, J.T., Jabs, D.A., Weinberg, D.V., Lewis, R.A., Davis, M.D., Friedberg, D.and Studies of Ocular Complications of AIDS (SOCA) Research Group. (2003) Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. Archives of Ophthalmology, 121, 99-107.
8. GlaxoSmithKline Inc. (2010) Valtrex (valacyclovir caplets) package insert.
9. Lowance, D., Neumayer, H.H., Legendre, C.M., Squifflet, J.P., Kovarik, J., Brennan, P.J., Norman, D., Mendez, R., Keating, M.R., Coggon, G.L., Crisp, A., and Lee, I.C. (1999) Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation: international valacyclovir cytomegalovirus prophylaxis transplantation study group. The New England Journal of Medicine, 340, 1462-1470.
10. Biron, K.K. (2006) Antiviral drugs for cytomegalovirus diseases. Antiviral Research, 71, 154-163.
11. Roche Laboratories Inc. (2009). Cytovene-IV (ganciclovir sodium for intravenous infusion only) and Cytovene (ganciclovir capsules for oral administration only) package insert.
12. Hodson, E.M., Jones, C.A.,Webster, A.C., Strippoli, G.F., Barclay, P.G., Kable, K., Vimalachandra, D., and Craig, J.C. (2005) Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet, 365, 2105-2115.
13. Cvetkovic, R.S. and Wellington, K. (2005) Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs, 65, 859-878.
14. Astra Zeneca Inc. (2000) Foscavir (foscarnet injection) package insert.
15. Gilead Sciences Inc. (1996) Vistide (cidofovir injection) package insert.
16. Ciesla, SL., Trahan, J., Wan, W.B., Beadle, J.R., Aldern, K.A., Painter, G.R., and Hostetler, K.Y. (2003) Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Research, 59, 163-171.
17. Rowshani, A.T., Bemelman, F.J., van Leeuwen, E.M., van Lier, R.A., and ten Berge, I.J. (2005) Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation, 79, 381-386.
18. Townsend, L.B. and Revankar, G.R. (1970) Benzimidazole nucleosides, nucleotides, and related derivatives. Chemical Reviews, 70, 389-438.
19. Zou, R., Drach, J.C., and Townsend, L.B. (1997) Design, synthesis, and antiviral evaluation of 2-chloro-5,6-dihalo-1-b-D-ribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections. Journal of Medicinal Chemistry, 40, 811-818.
20. Townsend, L.B., Drach, J.C., Good, S.S., DaLuge, S.M., and Martin, M.C. (1996) Therapeutic nucleosides. US Patent 5,534,535. Issued Sept. 7, 1996.
21. Underwood, M.R., Harvey, R.J., Stanat, S.C., Hemphill, M.L., Miller, T., Drach, J.C., Townsend, L.B., and Biron, K.K. (1998) Inhibition of HCMV DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. Journal of Virology, 72, 717-725.
22. Krosky, P.M., Underwood, M.R., Turk, S.R., Feng, K.W.-H., Jain, R.K., Ptak, R.G., Westerman, A.C., Biron, K.K., Townsend, L.B., and Drach, J.C. (1998) Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. Journal of Virology, 72, 4721-4728.
23. Bogner, E. (2002) Human cytomegalovirus terminase as a target for antiviral chemotherapy. Reviews inMedical Virology, 12, 115-127.
24. Dittmer, A., Drach, J.C., Townsend, L.B., Fischer, A., and Bogner, E. (2005) Interaction of the putative HCMV portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides. Journal of Virology, 79, 14660-14667.
25. Good, S.S., Owens, B.S., Townsend, L.B., and Drach, J.C. (1994) The disposition in rats and monkeys of 2-bromo-5,6-dichloro-1-(b-D-ribofuranosyl)-benzimidazole (BDCRB) and its 2,5,6-trichloro congener (TCRB). Antiviral Research, 23 (S1), 103.
26. Underwood, M.R., Ferris, R.G., Selleseth, D.W., Davis, M.G., Drach, J.C., Townsend, L.B., Biron, K.K., and Boyd, F.L. (2004) Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus. Antimicrobial Agents and Chemotherapy, 48, 1647-1651.
27. Biron, K.K., Guudmundson, K.S., and Drach, J.C. (2010) Benzimidazole ribonucleosides: Novel drug candidates for the prevention and treatment of cytomegalovirus disease, in Antiviral Drugs: Biology, Chemistry, Clinic (ed. W.M. Kazmierski), John Wiley & Sons, Inc., Hoboken, NJ, in press.
28. Townsend, L.B., Devivar, R.V., Turk, S.R., Nassiri, M.R., and Drach, J.C. (1995) Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(b-D-ribofuranosyl) benzimidazoles. Journal of Medicinal Chemistry, 38, 4098-4105.
29. Chamberlain, S.D., Daluge, S.M., and Koszalka, G.W. (1999) Antiviral benzimidazole nucleoside analogues and methods for their preparation. US patent 5,998,605. Issued July 12, 1999.
30. Williams, S.L., Hartline, C.B., Kushner, N.L., Harden, E.A., Bidanset, D.J., Drach, J.C., Townsend, L.B., Underwood, M.R., Biron, K.K., and Kern, E.R. (2003) In vitro activities of benzimidazole D-and L-ribonucleosides against herpesviruses. Antimicrobial Agents and Chemotherapy, 47, 2186-2192.
31. Biron, K.K., Harvey, R.J., Chamberlain, S.C., Good, S.S., Smith, A.A., 3rd, Davis, M.G., Talarico, C.L., Miller, W.H., Ferris, R., Dornsife, R.E., Stanat, S.C., Drach, J.C., Townsend, L.B., and Koszalka, G.W. (2002) Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrobial Agents and Chemotherapy, 46, 2365-2372.
32. McSharry, J.J., McDonough, A., Olson, B., Talarico, C., Davis, M., and Biron, K.K. (2001) Inhibition of ganciclovirsusceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. Clinical and Diagnostic Laboratory Immunology, 8, 1279-1281.
33. Chou, S., Van Wechel, L.C., and Marousek, G.I. (2006) Effect of cell culture conditions on the anticytomegalovirus activity of maribavir. Antimicrobial Agents and Chemotherapy, 50, 2557-2559.
34. Zacny, V.I., Gershburg, E., Davis, M.G., Biron, K.K., and Pagano, J.S. (1999) Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5,6-dichloro-2-(isopropylamino)1-beta-Lribofuranosyl-1H-benzimidazole. Journal of Virology, 73, 7271-7277.
35. Kern, E.R., Hartline, C.B., Rybak, R.J., Drach, J.C., Townsend, L.B., Biron, K.K., and Bidanset, D.J. (2004) Activities of benzimidazole D-and L-ribonucleosides in animal models of cytomegalovirus infections. Antimicrobial Agents and Chemotherapy, 48, 1749-1755.
36. Drew, W.L., Minor, R.C., Marousek, G.L., and Chou, S. (2006) Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. Journal of Clinical Virology, 37, 124-127.
37. Chou, S. (2008) Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Reviews in Medical Virology, 18, 233-246.
38. Biron, K.K., Fyfe, J.A., Stanat, S.C., Leslie, L.K., Sorrell, J.B., Lambe, C.U., and Coen, D.M. (1986) A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy] methyl)guanine (BW B759U) induces reduced levels ofBWB759U triphosphate. Proceedings of the National Academy of Sciences of the United States of America, 83, 8769-8773.
39. Sullivan, V., Talarico, C.L., Stanat, S.C., Davis, M., Coen, D.M., and Biron, K.K. (1992) A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature, 359, 85.
40. Chou, S. and Marousek, G.I. (2008) Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. Journal of Virology, 82, 246-253.
41. Truesdale, A.T., Biron, K.K., Ellis, B.P., Miller,W.H., and Wood, E.R. (2007) Mode of inhibition studies with MBV and the CMV kinase UL97. 32nd International Herpesvirus Workshop, Asheville, N.C. (Abst. 10.27).
42. Chee, M.S., Lawrence, G.L., and Barrell, B.G. (1989) Alpha-, beta-and gammaherpesviruses encode a putative phosphotransferase. The Journal of General Virology, 70, 1151-1160.
43. Hanks, S.K., Quinn, A.M., and Hunter, T. (1988) The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science, 241, 42-52.
44. Smith, R.F. and Smith, T.F. (1989) Identification of new protein kinaserelated genes in three herpesviruses, herpes simplex virus, varicella-zoster virus, and Epstein-Barr virus. Journal of Virology, 63, 450-455.
45. Prichard, M.N. (2009) Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Reviews in Medical Virology, 19, 215-229.
46. Coulter, L.J., Moss, H.W., Lang, J., and McGeoch, D.J. (1993) A mutant of herpes simplex virus type 1 in which the UL13 protein kinase gene is disrupted. The Journal of General Virology, 74, 387-395.
47. Moffat, J.F., Zerboni, L., Sommer, M.H., Heineman, T.C., Cohen, J.I., Kaneshima, H., and Arvin, A.M. (1998) The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human Tcells and skin in the SCID-hu mouse. Proceedings of the National Academy of Sciences of the United States of America, 95, 11969-11974.
48. Gershburg, E. and Pagano, J.S. (2002) Phosphorylation of the Epstein-Barr (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94. Journal of Virology, 76, 998-1003.
49. Wang, F.Z., Roy, D., Gershburg, E., Whitehurst, C.B., Dittmer, D.P., and Pagano, J.S. (2009) Maribavir inhibits Epstein-Barr virus transcription in addition to viral DNA replication. Journal of Virology, 83, 12108-12117.
50. Jault, F.M., Jault, J.M., Ruchti, F., Fortunato, E.A., Clark, C., Corbeil, J., Richman, D.D., and Spector, D.H. (1995) Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. Journal of Virology, 69, 6697-6704.
51. Tamm, I. and Sehgal, P.B. (1978) Halobenzimidazole ribosides and RNA synthesis of cells and viruses. Advances in Virus Research, 22, 187-258.
52. Koszalka, G.W., Johnson, N.W., Good, S.S., Boyd, L., Chamberlain, S.C., Townsend, L.B., Drach, J.C., and Biron, K.K. (2002) Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrobial Agents and Chemotherapy, 46, 2373-2380.
53. Zimmermann, A., Wilts, H., Lenhardt, M., Hahn, M., and Mertens, T. (2000) Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase. Antiviral Research, 48, 49-60.
54. Schleiss, M., Eickhoff, J., Auerochs, S., Leis, M., Abele, S., Choi, Y., Anderson, J., Scott, G., Rawlinson, W., Rechter, S., Michel, D., Ensminger, S., Klebl, B., Stamminger, T., and Marschall, M. (2008) Protein kinase inhibitors of the quinazoline class exert anticytomegalovirus activity in vitro and in vivo. Antiviral Research, 79, 49-61.
55. Prichard, M.N., Gao, N., Jairath, S., Mulamba, G., Krosky, P., Coen, D.M., Parker, B.O., and Pari, G.S. (1999) A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. Journal of Virology, 73, 5663-5670.
56. Wolf, D.G., Courcelle, C.T., Prichard, M.N., and Mocarski, E.S. (2001) Distinct and separate roles for herpesvirusconserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proceedings of the National Academy of Sciences of the United States of America, 98 1895-1900.
57. Kamil, J.P. and Coen, D.M. (2007)Human cytomegalovirus protein kinase UL97 forms a complex with the tegument phosphoprotein pp65. Journal of Virology, 81, 10659-10668.
58. Prichard, M.N., Britt, W.J., Daily, S.L., Hartline, C.B., and Kern, E.R. (2005) Human cytomegalovirus UL97 kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. Journal of Virology, 79, 15494-15502.
59. Krosky, P.M., Baek, M.C., and Coen, D.M. (2003) The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. Journal of Virology, 77, 905-914.
60. Baek, M.C., Krosky, P.M., and Coen, D.M. (2002) Relationship between autophosphorylation and phosphorylation of exogenous substrates by the human cytomegalovirus UL97 protein kinase. Journal of Virology, 76, 11943-11952.
61. Krosky, P.M., Baek, M.C., Jahng, W.J., Barrera, I.,Harvey, R.J., Biron, K.K., Coen, D.M., and Sethna, P.B. (2003) The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. Journal of Virology, 77, 7720-7727.
62. Marschall, M., Freitag, M., Suchy, P., Romaker, D., Kupfer, R., Hanke, M., and Stamminger, T. (2003) The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44. Virology, 311, 60-71.
63. Baek, M.C., Krosky, P.M., Pearson, A., and Coen, D.M. (2004) Phosphorylation of the RNA polymerase II carboxylterminal domain in human cytomegalovirus-infected cells and in vitro by the viral UL97 protein kinase. Virology, 324, 184-193.
64. Kawaguchi, Y., Matsumura, T., Roizman, B., and Hirai, K. (1999)Cellular elongation factor 1delta is modified in cells infected with representative alpha-, beta-, or gammaherpesviruses. Journal of Virology, 73, 4456-4460.
65. Kawaguchi, Y. and Kato, K. (2003) Protein kinases conserved in herpesviruses potentially share a function mimicking the cellular protein kinase cdc2. Reviews in Medical Virology, 13, 331-340.
66. Schang, L.M., St Vincent, M.R., and Lacasse, J.J. (2006) Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antiviral Chemistry & Chemotherapy, 17, 293-320.
67. Marschall, M.,Marzi, A., aus dem Siepen, P., Jochmann, R., Kalmer, M., Auerochs, S., Lischka, P., Leis, M., and Stamminger, T. (2005) Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina. The Journal of Biological Chemistry, 280, 33357-33367.
68. Hume, A.J., Finkel, J.S., Kamil, J.P., Coen, D.M., Culbertson, M.R., and Kalejta, R.F. (2008) Phosphorylation of retinoblastoma protein by viral protein with cyclindependent kinase function. Science, 320, 797-799.
69. Prichard, M.N., Sztul, E., Daily, S.L., Perry, A.L., Frederick, S.L., Gill, R.B., Hartline, C.B., Streblow, D.N., Varnum, S.M., Smith, R.D., and Kern, E.R. (2008) Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes. Journal of Virology, 82, 5054-5067.
70. Komazin, G., Ptak, R.G., Emmer, B.T., Townsend, L.B., and Drach, J.C. (2003) Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. Journal of Virology, 77, 11499-11506.
71. Chou, S., Marousek, G.I., Senters, A.E., Davis, M.G., and Biron, K.K. (2004) Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. JournalofVirology,78,7124-7130.
72. Chou, S. (2009) Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrobial Agents and Chemotherapy, 53, 81-85.
73. Biron, K. (2006) Maribavir: a promising new antiherpes therapeutic agent, in New Concepts of Antiviral Therapy (eds E. Bogner and A. Holzenburg), Springer, pp. 309-366.
74. Chou, S. and Marousek, G.I. (2006) Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrobial Agents and Chemotherapy, 50, 3470-3472.
75. Evers, D.L., Komazin, G., Shin, D., Hwang, D.D., Townsend, L.B., and Drach, J.C. (2002) Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus. Antiviral Res., 56 (1), 61-22.
76. Wang, L.H., Peck, R.W., Yin, Y., Allanson, J., Wiggs, R., and Wire, M.B. (2003) Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrobial Agents and Chemotherapy, 47, 1334-1342.
77. Lalezari, J.P., Aberg, J.A., Wang, L.H., Wire, M.B., Miner, R., Snowden, W., Talarico, C.L., Shaw, S., Jacobson, M.A., and Drew, W.L. (2002) Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrobial Agents and Chemotherapy, 46, 2969-2976.
78. Hendrix, C., Kuppermann, B.D., Dunn, J.P., Wang, L.H., Starns, E., Snowden, B.W., Hamzeh, F., and Wire, M.B. (2000) A phase I trial to evaluate the ocular (intravitreal) penetration of 1263W94 after multiple dose, oral administration in AIDS patients with CMV retinitis. Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario.
79. Deayton, J.R., Wilson, P., Sabin, C.A., Davey, C.C., Johnson, M.A., Emery, V.C., and Griffiths, P.D. (2000) Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS (London, England), 14, 1163-1170.
80. ViroPharma Incorporated (2005) Form 10-K for the Fiscal Year Ended December 31, 2004.
81. Winston, D.J., Young, J.A., Pullarkat, V., Papanicolaou, G.A., Vij, R., Vance, E., Alangaden, G.J., Chemaly, R.F., Petersen, F., Chao, N., Klein, J., Sprague, K.,Villano, S.A., and Boeckh, M. (2008) Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood, 111, 5403-5410.
82. ViroPharma Incorporated (2008) Form 10-K for the fiscal year ended December 31, 2007.
83. Goldwater, D.R., Dougherty, C., Schumacher, M., and Villano, S.A. (2008) Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults. Antimicrobial Agents and Chemotherapy, 52, 1794-1798.
84. Ma, J.D., Nafziger, A.N., Villano, S.A., Gaedigk, A., and Bertino, J.S., Jr. (2006) Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrobial Agents and Chemotherapy, 50, 1130-1135.
85. Pescovitz, M.D., Bloom, R., Pirsch, J., Johnson, J., Gelone, S., and Villano, S.A. (2009) A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. American Journal of Transplantation, 9, 2324-2330.
86. Swan, S.K., Smith, W.B., Marbury, T.C., Schumacher, M., Dougherty, C., Mico, B.A., and Villano, S.A. (2007) Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment. Journal of Clinical Pharmacology, 47, 209-217.
87. www.clinicaltrials.gov (accessed June 25, 2010).
88. ViroPharma Incorporated (2009) Form 10-K for the fiscal year ended December 31, 2008.
89. Avery, R., Marty, F., Strasfeld, L., Lee, I., Arrieta, A., Chou, S., and Villano, S. (2009) Oral maribavir (MBV) for treatment of resistant or refractory cytomegalovirus (CMV) infections in transplant recipients. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California.
90. Strasfeld, L., Lee, I., Tatarowicz, W., Villano, S., and Chou, S. (2010) Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. The Journal of Infectious Diseases, 202, 104-108.